HCV-uninfected men with mean age of 55 years, 56% White and 29% Black. Incident CVD event rates were similar between the two groups (13.2 and 13.4 events/1000 person-years), with a higher incidence of coronary heart disease events in the HCVuninfected group and of stroke events in the HCV-infected group. Adjusting for ASCVD risk score, HCV infection was associated with higher risk for an ASCVD event in the subgroup with baseline ASCVD risk ≥7.5% (HR: 1.19, P<.0001). C-statistics were poor in both the HCV-infected and uninfected groups (0.60 and 0.61, respectively). By Hosmer-Lemeshow test, the ASCVD risk equation overestimated risk amongst lower risk patients and underestimated risk amongst higher risk patients in both the HCV-infected and uninfected groups. Further investigation is needed to determine whether a modified equation to accurately predict ASCVD risk in HCVinfected persons is warranted.
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| INTRODUCTION
Data from an increasing number of studies suggest that chronic hepatitis C virus (HCV) infection is independently associated with an increased risk for cardiovascular disease (CVD). [1] [2] [3] [4] [5] [6] [7] [8] Current American
College of Cardiology/American Heart Association guidelines recommend use of the Pooled Cohort atherosclerotic cardiovascular disease (ASCVD) risk equation for assessment of 10-year CVD risk 9 ;
however, this equation has not been validated in HCV-infected populations. Two of the ASCVD components, prevalence of hypertension and total cholesterol, are decreased in the setting of HCV infection.
Lower serum cholesterol in HCV-infected persons has been noted in numerous studies and is independent of degree of liver disease. 
| MATERIALS AND METHODS

| Subject selection/cohort derivation
We conducted a retrospective analysis utilizing the national HCV-uninfected subjects who subsequently had a positive HCV serology or viral load during the follow-up period were also excluded. Figure 1 illustrates the derivation of the cohort.
The primary outcomes were as follows: (i) incident MI, defined as one inpatient or two outpatient ICD-9 codes with date of diagnosis >6 months after study entry, (ii) incident coronary heart disease (CHD), defined as incident MI, CABG and/or PTCA occurring >6 months after entry, by one inpatient or two outpatient ICD-9 codes, (iii) incident stroke, defined as one inpatient or two outpatient ICD-9 codes with date of diagnosis >6 months after study entry, (iv) incident ASCVD event, defined as incident CHD plus stroke occurring 6 months after entry and (v) incident ASCVD event plus death from any cause.
Incident ASCVD event plus death was examined as an outcome to explore potential cardiovascular-related deaths that would not have been captured by an ICD-9 code for a CVD event. We examined the Pooled Cohort Equation ASCVD risk score, calculated for each participant using the published sex and race-specific equations, 18 as a predictor for the above outcomes.
| Statistical analysis
Baseline demographic and clinical characteristics and ASCVD risk score and risk category (low, <7.5% vs high, ≥7.5%) were examined and compared between HCV-infected and uninfected controls using Calibration of the score was measured by Hosmer-Lemeshow statistic, comparing observed vs predicted 10-year risk by deciles of predicted risk. All analyses were performed using SAS 9.4 (Cary, NC, USA).
| Institutional review board approval
The study was determined by the University of California, Los Angeles
Institutional Review Board (IRB) to be exempt from IRB review.
ERCHIVES is approved by the IRB at VA Pittsburgh Healthcare System.
| RESULTS
A total of 70 490 HCV-infected and 97 766 HCV-uninfected male participants were included in the cohort. Baseline characteristics of the cohort are summarized in Table 1 and in Table 2 , stratified by ASCVD risk category (<7.5% and ≥7.5%). The HCV-infected and uninfected groups were similar in age and distribution of race and ethnicity, prevalence of diabetes, systolic blood pressure, baseline treatment with antihypertensive medication and HDL levels. The HCV-infected group had slightly lower body mass index, higher alanine aminotransferase (ALT) levels and lower total cholesterol, LDL and triglyceride levels.
HCV-infected participants were likely less likely to be on lipid-lowering therapy and more likely to be a current smoker and have a history of alcohol or drug abuse. Average predicted 10-year risk for first ASCVD event based on baseline characteristics was the same, 14% in both the HCV-infected and uninfected groups. The majority (approximately 70%) of patients in both groups had high predicted ASCVD risk ≥7.5%.
Amongst the high ASCVD risk group, only 25.3% of HCV-infected persons were on statin therapy compared to 45.1% of HCV-uninfected persons ( Table 2) . Amongst both the HCV-infected and HCVuninfected groups, the ASCVD risk score (high vs low) appeared driven by similar magnitudes of difference in the risk equation components of age, race, blood pressure, diabetes and total and HDL cholesterol.
Unadjusted event rates for incident MI, CHD, stroke, ASCVD and ASCVD + death during the follow-up period are presented in Table 3 .
Rates of incident MI and CHD were higher amongst HCV-uninfected persons than HCV-infected persons, whereas the rate of incident stroke was higher amongst HCV-infected persons. Overall, the incident ASCVD rate was not different between the groups, but the rate of death from any cause was higher amongst HCV-infected than in (Table 4a ). Adjusting for ASCVD score, amongst participants with low predicted ASCVD risk (<7.5%), HCV infection was associated with a 41% lower risk for incident ASCVD event, whereas amongst participants with high predicted ASCVD risk (≥7.5%), HCV infection was associated with a 19% higher risk for incident ASCVD event (Table 4b) . HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
T A B L E 1 Baseline characteristics of the cohort and predicted 10-year ASCVD risk by HCV status
| Performance of the ASCVD risk score
| Discrimination of ASCVD risk by the ASCVD risk score in HCV-infected and uninfected persons in the cohort
Examining C-statistics in the HCV-infected and uninfected groups and within each group by race (White, Black, other), the ASCVD risk score performed poorly in discriminating between individuals who had an ASCVD event and those who did not across all groups, with C-statistic values of 0.58-0.63 (see Table 5 ). HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. 
| Calibration of the ASCVD risk score for HCVinfected and uninfected persons in the cohort
| DISCUSSION
We found that the performance of the ASCVD risk score and the impact of HCV infection on incident CVD events in our cohort varied depending on the level of ASCVD risk. While in the overall cohort, there
was not an independent association of HCV with incident ASCVD risk, the association of HCV with ASCVD risk was modified by estimated ASCVD risk score. At higher predicted risk (≥7.5%), HCV was associated with increased risk for an ASCVD event, whereas at lower risk (<7.5%), HCV was associated with decreased risk for an ASCVD HCV, hepatitis C virus; MI, myocardial infarction; CHD, coronary heart disease; ASCVD, atherosclerotic cardiovascular disease.
event. Correspondingly, examining the calibration of the ASCVD risk equation for prediction of ASCVD event, it appears that the equation performs well (observed and predicted number of events being similar) for the average risk patient in the cohort, but performs poorly at lower and higher risk. This is of particular concern with higher risk patients, where ASCVD risk appears to be underestimated. Notably, in the cohort, HCV-infected persons were much less likely than HCVuninfected persons to be on a lipid-lowering medication, and only 21% of HCV-infected patients were on a lipid-lowering agent, despite the majority (71%) having an ASCVD risk score ≥7.5%. This discrepancy suggests under-treatment for CVD prevention in HCV-infected persons, perhaps driven by both low cholesterol levels (well established now to be associated with chronic HCV infection) and unproven concern for hepatotoxicity with statin therapy, 19, 20 and highlights a missed opportunity for CVD prevention.
Based on traditional risk factors included in the ASCVD risk equation, there was no difference in calculated ASCVD risk score between HCV-infected and uninfected subjects. We also interestingly found no difference in overall incident ASCVD event rates comparing HCV-infected and uninfected patients. However, there appear to be potential differences in the type of ASCVD event experienced by HCV-infected and uninfected persons, with higher rates of coronary disease events (incident MI and CHD) amongst HCV-uninfected persons compared to a higher rate of stroke amongst HCV-infected persons in our cohort. The association of HCV with ischaemic stroke and carotid atherosclerosis has been reported in multiple studies, where HCV infection was associated with both higher risk of stroke and younger age at stroke event. 10, 21 Interestingly, HCV has been isolated in carotid plaque, including in patients without detectable serum HCV RNA. 22 Data published previously from ERCHIVES demonstrated higher rates of CVD amongst HCV-infected persons compared to uninfected controls after adjustment for traditional risk factors, but CHF was included in the CVD definition (whereas we focused in this analysis on atherosclerotic CVD), 2 which may have driven the higher CVD event rates in the HCV-infected group. The association of HCV infection with heart failure is supported by other studies. 8, 23 We also saw higher rates of death amongst HCV-infected vs HCV-uninfected subjects, some of which may have been cardiac-related deaths, but cause of death was not available for analysis.
In our analysis, the ASCVD risk equation performed poorly by C- Gilead. All other authors report no conflicts of interest.
